Skip to main content

Table 3 In vitro antifungal susceptibility of C. albicans between mono-CA-BSI and mixed-CA/B-BSIs

From: Clinical characteristics, risk factors and outcomes of mixed Candida albicans/bacterial bloodstream infections

Candida species Antifungalagent mono-CA-BSI(n = 93) mixed-CA/B-BSIs(n = 24) P value
Number of strains Drug sensitivity Number of strains Drug sensitivity
S I R S I R
C.albicans Fluconazole(n = 104) a 85(91.3%) 81(95.3%) 4(4.7%) 0 19(79.1%) 19(100.0%) 0 0 > 0.999
Clotrimazole(n = 69) a 55(59.1%) 54(98.2%) 0 1(1.8%) 15(62.5%) 14(93.3%) 0 0 0.901
Ketoconazole(n = 60) a 45(48.3%) 19(42.2%) 15(33.3%) 11(24.4%) 15(62.5%) 7(46.7%) 6(40.0%) 2(13.3%) 0.764
Itraconazole(n = 111) a 89(95.7%) 86(96.6%) 1(1.1%) 2(2.2%) 22(91.7%) 21(95.5%) 1(4.5%) 0 > 0.999
Amphotericin B (n = 111) a 90(96.8%) 90(100.0%) 0 0 21(87.5%) 21(100.0%) 0 0 > 0.999
Nystatin(n = 68) a 56(60.2%) 55(98.2%) 1(1.8%) 0 12(50.0%) 12(100.0%) 0 0 > 0.999
5-fluorocytosine(n = 38) a 31(33.3%) 30(96.8%) 0 1(3.2%) 7(29.1%) 7(100.0%) 0 0 > 0.999
Voriconazole(n = 103) a 82(88.2%) 82(100.0%) 0 0 21(87.5%) 21(100.0%) 0 0 > 0.999
  1. S sensitive, I intermediary, R resistant
  2. aNot all agents listed tested in all isolates